AUTHORS
John F. Seymour, MBBS, PhD, Jennifer R. Brown, MD, PhD2, Paolo Ghia, MD, PhD3, Barbara Eichhorst, MD4, Jiefen Munley5, Batul Suterwala6, Kara Miller, MS7, Toshifumi Fujimori, PhD8, Alen Ostojic, MD9, Arnon Philip Kater, MD, PhD10
AFFILIATIONS
1 Peter MacCallum Cancer Centre, Royal Melbourne Hospital, The University of Melbourne, Melbourne, Australia
2 Dana-Farber Cancer Institute, Boston, United States
3 IRCCS Ospedale San Raffaele, Milano, Italy, Università Vita-Salute San Raffaele, Milano, Italy
4 University Hospital Cologne, Center for Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf, Cologne, Germany
5 AstraZeneca, Wilmington, United States
6 AstraZeneca, South San Francisco, United States
7 AstraZeneca, South San Francisco, United States
8 AstraZeneca, Cambridge, United Kingdom
9 AstraZeneca, Barcelona, Spain
10 Amsterdam University Medical Center, Amsterdam, on behalf of HOVON, Netherlands
ABSTRACT
Introduction: The AMPLIFY trial in patients (pts) with treatment-naive (TN) chronic lymphocytic leukemia (CLL) demonstrated significantly prolonged progression-free survival with fixed-duration acalabrutinib + venetoclax ± obinutuzumab (AV/AVO) vs chemoimmunotherapy (CIT) and a manageable safety profile (Brown et al. NEJM 2025). While V-containing regimens have been associated with risk of tumor lysis syndrome (TLS) (Furstenau et al. ASH 2021), TLS was limited to laboratory TLS with AV and AVO (n=1 each) in AMPLIFY (Seymour et al. ASH 2025). These data suggest 2-mo A lead-in may result in significant disease debulking, reducing TLS risk. We provide an in-depth description of TLS in the AMPLIFY AV and AVO arms.
Methods: AMPLIFY (NCT03836261) is a randomized, phase 3 trial in pts aged ≥18 y with TN CLL, ECOG PS ≤2, and no del(17p) or TP53 mutations. Pts were randomized 1:1:1 to AV (A, cycles [C] 1–14; V, C3–C14), AVO (AV as noted; O C2–7), or CIT (C1–6). Pts at risk of TLS (high tumor burden [TB], high absolute lymphocyte count [ALC], and/or renal impairment [RI]) received TLS prophylaxis (hydration and antihyperuricemics), with high TB defined as any lymph node (LN) ≥10 cm or any LN ≥5 cm and ALC ≥25x109/L; high ALC defined as >25x109/L; and RI as creatinine clearance (Cr) <70 mL/min. Descriptive analyses included LN size (long axis diameter of the largest measurable LN by computed tomography); TB at C1 day (D) 1 and C3D1 (low, medium+Cr≥80 mL/min, medium+Cr<80 [reported separately due to hospitalization indication for initial V dosing], and high); TB reduction; prophylactic intravenous (IV) fluid treatment over time; incidence of laboratory/clinical TLS (Howard criteria); and incidence of/treatment for laboratory chemistry abnormality adverse events (AEs; hyperkalemia, hyperphosphatemia, hyperuricemia, creatinine increased).
Results: In total, 577 pts were randomized to AV (n=291) or AVO (n=286). Any study treatment was initiated by 291 pts in the AV arm and 284 in the AVO arm. Five pts in the AV arm and 8 pts in the AVO arm did not initiate V (for reasons other than TLS). At C1D1, median (range) LN size was 4.2 (1.5–27.0) cm in the AV arm and 4.0 (1.5–25.5) cm in the AVO arm. At C3D1 after 2 cycles of A lead-in, median (range) LN size was 2.3 (0–17.0) cm (AV arm) and 2.1 (0–12.2) cm (AVO arm). Laboratory TLS occurred in 1 pt in the AV arm (starting C3D2 [at V 20 mg], lasting 14 d) and 1 pt in the AVO arm (starting C1D28 [before VO initiation], lasting 9 d); no clinical TLS occurred.
At C1D1, TB was low in 38 and 44 pts (AV and AVO, respectively), medium+Cr≥80 in 81 and 87 pts, medium+Cr<80 in 76 and 60 pts, and high in 74 and 60 pts. C1D1 TB was missing in 22 (AV) and 32 (AVO) pts; 1 pt (AVO) had medium TB with missing Cr. At C3D1, TB was low in 81 and 222 pts (AV and AVO, respectively), medium+Cr≥80 (n=102; n=26), medium+Cr<80 (n=77; n=19), and high (n=25; n=9), with missing TB in 6 and 7 pts.
Among pts (AV and AVO, respectively) with high TB at C1D1, most (75.7%; 85.0%) had reduced TB by C3D1; 12 (16.2%) and 35 (58.3%) moved to low, 28 (37.8%) and 10 (16.7%) moved to medium+Cr≥80, 16 (21.6%) and 6 (10.0%) moved to medium+Cr<80, and 18 (24.3%) and 6 (10.0%) remained high. Among pts (AV and AVO, respectively) with medium+Cr≥80 TB at C1D1, 18 (22.2%) and 68 (78.2%) moved to low TB at C3D1, and among pts with medium+Cr<80 at C1D1, 23 (30.3%) and 49 (81.7%) moved to low TB at C3D1.
During V ramp-up, isolated laboratory chemistry abnormality AEs were reported in 16 (5.6%) pts in the AV arm and 5 (1.8%) pts in the AVO arm; 12 (4.2%) and 3 (1.1%), respectively, received medication for these AEs. The isolated laboratory chemistry abnormality AEs occurring during V ramp-up included hyperkalemia in 4 (1.4%) in the AV arm and 2 (0.7%) in the AVO arm, hyperphosphatemia in 6 (2.1%) and 2 (0.7%), hyperuricemia in 7 (2.5%) and 1 (0.4%), and creatinine increased in 1 (0.4%) and 0 pts, respectively. Prophylactic IV fluid was administered to 28 pts in the AV arm and 20 in the AVO arm during wk 1 of V ramp-up, 18 and 8 pts during wk 2, 6 and 2 pts during wk 3, 5 and 2 pts during wk 4, and 4 and 8 pts during wk 5, respectively.
Conclusion: In AMPLIFY, 2 laboratory TLS events (1 per arm) occurred, with no clinical TLS. One event occurred during V ramp-up (AV); the other occurred prior to V initiation (AVO). Acalabrutinib lead-in coupled with prophylaxis was associated with effective debulking and a very low incidence of laboratory TLS.
DISCLOSURES
John F. Seymour, MBBS, PhD: BMS - Honoraria; BeOne - Honoraria; Gilead - Honoraria; AstraZeneca - Honoraria; Roche - Honoraria; AbbVie - Honoraria; Loxo - Honoraria; Janssen - Honoraria; Roche - Research Funding; AbbVie - Research Funding; Janssen - Research Funding; BMS - Research Funding; Loxo - Research Funding; BMS - Consultancy (Includes expert testimony); TG Therapeutics - Consultancy (Includes expert testimony)